The Korea Research-based Pharma Industry Association (KRPIA) and others have submitted an opinion disagreeing with the proposed legislation that would introduce a maximum cap for terms of patent protection for new drugs. The proposed legislation is intended to facilitate an earlier market launch for Korea-made new drugs. The Korean Intellectual Property Office (KIPO) stated its opposition to this issue at the 21st National Assembly.

At that time, KIPO stressed that the original draft instead of a revised Patent Law that would limit the number of patents to a single (1 patent).

A similar proposed legislation has been submitted to the 22nd National Assembly. Therefore, it is highly likely